TY - JOUR T1 - Initial bromocriptine did not change mortality in early, mild Parkinson's disease JF - Evidence Based Medicine JO - Evid Based Med SP - 91 LP - 91 DO - 10.1136/ebm.7.3.91 VL - 7 IS - 3 A2 - , Y1 - 2002/05/01 UR - http://ebm.bmj.com/content/7/3/91.abstract N2 - (2001) Neurology 57, 1687. Lees AJ, Katzenschlager R, Head J, et al, on behalf of the Parkinson's Disease Research Group of the United Kingdom.. Ten-year follow-up of three different initial treatments in de-novo PD. A randomized trial.. Nov 13;. :. –94.OpenUrlAbstract/FREE Full Text 
 
 QUESTION: In patients with early, mild Parkinson's disease (PD), does the long term effectiveness of levodopa alone differ from that of levodopa plus selegiline or initial bromocriptine monotherapy? Randomised {allocation concealed*}†, blinded {data safety and monitoring committee}†,* controlled trial with a mean 9.2 years of follow up. UK. 782 patients with a clinical diagnosis of PD. Exclusion criteria were failure to respond to an adequate trial of dopaminergic drugs or incapacitating cognitive impairment. 249 patients were allocated to levodopa alone, 271 to levodopa plus selegiline, and 262 to initial bromocriptine. 104 patients in the bromocriptine group were rerandomised to 1 of the other 2 treatment groups after bromocriptine was withdrawn, but all patients were analysed in the groups to which they were initially randomised. Mortality, disability, and adverse effects. … ER -